Randomized crossover study of the efficacy and safety of sevelamer hydrochloride and lanthanum carbonate in Japanese patients undergoing hemodialysis.

Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 20120801

Effects of phosphate binders in moderate CKD.

Journal of the American Society of Nephrology : JASN 20120801

Case of proximal calciphylaxis with protein S deficiency, successfully treated with multimodality therapy.

The Journal of dermatology 20120701

Enhancement and restriction of chain motion in polymer networks.

International journal of pharmaceutics 20120701

Dissociation between progression of coronary artery calcification and endothelial function in hemodialysis patients: a prospective pilot study.

Clinical nephrology 20120701

Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in dialysis patients: a Canadian payer perspective.

Clinical therapeutics 20120701

[Kidney and bone update : the 5-year history and future of CKD-MBD. Pharmacoeconomics in the field of CKD-MBD].

Clinical calcium 20120701

[Kidney and bone update : the 5-year history and future of CKD-MBD. Progress of phosphate binders].

Clinical calcium 20120701

Effects of sevelamer on HbA1c, inflammation, and advanced glycation end products in diabetic kidney disease.

Clinical journal of the American Society of Nephrology : CJASN 20120601

Effect of gastric acid suppression with pantoprazole on the efficacy of sevelamer hydrochloride as a phosphate binder in haemodialysis patients: a pilot study.

Nephrology (Carlton, Vic.) 20120501

Potential influence of sevelamer hydrochloride on responsiveness to erythropoiesis-stimulating agents in haemodialysis patients.

Nephrology (Carlton, Vic.) 20120301

Mortality in kidney disease patients treated with phosphate binders: a randomized study.

Clinical journal of the American Society of Nephrology : CJASN 20120301

Lanthanum carbonate, like sevelamer-HCl, retards the progression of vascular calcification and atherosclerosis in uremic apolipoprotein E-deficient mice.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20120201

Comparison of calcium acetate and sevelamer on vascular function and fibroblast growth factor 23 in CKD patients: a randomized clinical trial.

American journal of kidney diseases : the official journal of the National Kidney Foundation 20120201

Potential interaction between sevelamer and fat-soluble vitamins: a hypothesis.

American journal of kidney diseases : the official journal of the National Kidney Foundation 20120201

Role of uremic toxins and oxidative stress in the development of chronic kidney disease-mineral and bone disorder.

Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation 20120101

Effects of phosphonoformic acid and renagel on renal type IIa sodium-dependent phosphate cotransporter mRNA expression in hyperphosphatemia rats.

Renal failure 20120101

Fibroblast growth factor-23 helps explain the biphasic cardiovascular effects of vitamin D in chronic kidney disease.

International journal of biological sciences 20120101

Assessment of phosphate binding by sevelamer carbonate powder for oral suspension mixed in foods.

Nephrology nursing journal : journal of the American Nephrology Nurses' Association 20120101

Multi-intervention management of calciphylaxis: a report of 7 cases.

American journal of kidney diseases : the official journal of the National Kidney Foundation 20111201

CKD-mineral and bone disorder: core curriculum 2011.

American journal of kidney diseases : the official journal of the National Kidney Foundation 20111201

C-reactive protein levels are associated with arterial media calcification in nondiabetic patients with end-stage renal disease on long-term hemodialysis.

Clinical nephrology 20111201

Cost-effectiveness of lanthanum carbonate versus sevelamer hydrochloride for the treatment of hyperphosphatemia in patients with end-stage renal disease: a US payer perspective.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20111201

Impact of non-traditional phosphate binders and cinacalcet on haemodialysis patient biochemistry, pill burden and cost.

Nephrology (Carlton, Vic.) 20111101

The pathophysiology of early-stage chronic kidney disease-mineral bone disorder (CKD-MBD) and response to phosphate binders in the rat.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20111101

Efficacy and safety of SBR759, a novel calcium-free, iron(III)-based phosphate binder, in Asian patients undergoing hemodialysis: A 12-week, randomized, open-label, dose-titration study versus sevelamer hydrochloride.

Nephrology (Carlton, Vic.) 20111101

Does concomitant administration of sevelamer hydrochloride and lanthanum carbonate modify the control of phosphatemia?

European review for medical and pharmacological sciences 20111101

A study of maintenance therapy after intravenous maxacalcitol for secondary hyperparathyroidism.

Clinical nephrology 20111001

Effectiveness and cost-efficacy of phosphate binders in hemodialysis.

Annals of nutrition & metabolism 20111001

Calcium carbonate, but not sevelamer, is associated with better outcomes in hemodialysis patients: results from the French ARNOS study.

Hemodialysis international. International Symposium on Home Hemodialysis 20111001

Pharmacology, efficacy and safety of oral phosphate binders.

Nature reviews. Nephrology 20110906

Effect of phosphate binders on serum inflammatory profile, soluble CD14, and endotoxin levels in hemodialysis patients.

Clinical journal of the American Society of Nephrology : CJASN 20110901

A randomized controlled trial of oral phosphate binders in the treatment of pseudoxanthoma elasticum.

Journal of the American Academy of Dermatology 20110801

Diffuse uremic tumoral calcinosis in a patient on long-term hemodialysis.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 20110801

Biomechanical properties of bones from rats treated with sevelamer.

Collegium antropologicum 20110601

Lanthanum carbonate provides control of phosphorus levels in patients new to phosphate binder therapy and patients changed from other phosphate binders.

Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation 20110501

The effect of sevelamer carbonate and lanthanum carbonate on the pharmacokinetics of oral calcitriol.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20110501

Comparison of dietary phosphate absorption after single doses of lanthanum carbonate and sevelamer carbonate in healthy volunteers: a balance study.

American journal of kidney diseases : the official journal of the National Kidney Foundation 20110501

Is combined calcium/magnesium phosphate binder really noninferior to sevelamer hydrochloride?

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20110401

Uremic toxins and oral adsorbents.

Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 20110401

Sevelamer use and incidence of peritonitis in peritoneal dialysis.

Wiener klinische Wochenschrift 20110401

Does the choice of phosphate binder affect trace element levels in chronic kidney disease patients treated by regular haemodialysis?

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20110301

Effect of sevelamer and calcium-based phosphate binders on coronary artery calcification and accumulation of circulating advanced glycation end products in hemodialysis patients.

American journal of kidney diseases : the official journal of the National Kidney Foundation 20110301

Pharmacology of the phosphate binder, lanthanum carbonate.

Renal failure 20110301

Phosphate binders for preventing and treating bone disease in chronic kidney disease patients.

The Cochrane database of systematic reviews 20110216

Sevelamer prescriptions after reporting of the Dialysis Clinical Outcomes Revisited (DCOR) trial findings: An analysis of 5,495 patients receiving maintenance dialysis in Ontario, Canada.

American journal of kidney diseases : the official journal of the National Kidney Foundation 20110201

Lanthanum carbonate versus sevelamer hydrochloride: improvement of metabolic acidosis and hyperkalemia in hemodialysis patients.

Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 20110201

Development and validation of rapid ion-chromatographic method with conductivity detection for trace level determination of allylamine in sevelamer drug substances.

Journal of pharmaceutical and biomedical analysis 20110105

Fibroblast growth factor 23 in hemodialysis patients: effects of phosphate binder, calcitriol and calcium concentration in the dialysate.

Nephron. Clinical practice 20110101

Effect of sevelamer hydrochloride exposure on carotid intima media thickness in hemodialysis patients.

Nephron. Clinical practice 20110101

Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism.

Kidney international 20110101

Phosphate binder is not phosphate binder! Sevelamer may be different!

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20110101

Reduction of hyperphosphatemia is related with the reduction of C-reactive protein in dialysis patients. Study in sevelamer-resistant dialysis patients treated with chitosan chewing gum as salivary phosphate binder.

Renal failure 20110101

[Chronic kidney disease and atherosclerosis].

Nihon rinsho. Japanese journal of clinical medicine 20110101

Evaluating the effects of sevelamer carbonate on cardiovascular structure and function in chronic renal impairment in Birmingham: the CRIB-PHOS randomised controlled trial.

Trials 20110101

Pleiotropic effects of sevelamer beyond phosphate binding in end-stage renal disease patients: a randomized, open-label, parallel-group study.

Clinical drug investigation 20110101

Do aluminium-based phosphate binders continue to have a role in contemporary nephrology practice?

BMC nephrology 20110101

[Effect of non-calcium-based phosphate binders on vascular calcifications in patients on hemodialysis: clinical experience and hypotheses].

Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia 20110101

[The influence of short-term magnesium carbonate treatment on calcium-phosphorus balance in dialysis patients].

Wiadomosci lekarskie (Warsaw, Poland : 1960) 20110101

Regression of vascular calcification in a patient treated with cinacalcet: a case report.

Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20110101

Levothyroxine and sevelamer: listen to the patient.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20110101

Short-term efficacy of sevelamer versus calcium acetate in patients with chronic kidney disease stage 3-4.

International urology and nephrology 20101201

Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20101101

Sevelamer carbonate for the treatment of hyperphosphatemia in patients with kidney failure (CKD III - V).

Expert opinion on pharmacotherapy 20101101

[Treatment of hyperphosphatemia with sevelamer hydrochloride in CKD patients: effects on vascular calcification and mortality].

Clinical calcium 20101101

Benefits of sevelamer on markers of bone turnover in Taiwanese hemodialysis patients.

Journal of the Formosan Medical Association = Taiwan yi zhi 20100901

Serological cardiovascular and mortality risk predictors in dialysis patients receiving sevelamer: a prospective study.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20100801

Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia.

Leukemia research 20100701

Impact of phosphate binder type on coronary artery calcification in hemodialysis patients.

Clinical nephrology 20100701

Evaluation of morbidity and mortality data related to cardiovascular calcification from calcium-containing phosphate binder use in patients undergoing hemodialysis.

Pharmacotherapy 20100701

[CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). The impact of CKD-MBD on mortality].

Clinical calcium 20100701

[CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Parathyroid interventions: final one piece in the management of uremic SHPT patients].

Clinical calcium 20100701

Homocysteine and folic acid levels in hemodialysis patients treated with sevelamer hydrochloride.

Clinical nephrology 20100601

Sevelamer carbonate. No better than sevelamer hydrochloride.

Prescrire international 20100601

Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimension parameters.

Clinical journal of the American Society of Nephrology : CJASN 20100501

Total and individual coronary artery calcium scores as independent predictors of mortality in hemodialysis patients.

American journal of nephrology 20100501

[Secondary osteoporosis UPDATE. Therapy for bone-mineral disease in CKD-5D patients].

Clinical calcium 20100501

Oral phosphate binders in patients with kidney failure.

The New England journal of medicine 20100408

Sevelamer 'carbonate': what's in a name?

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20100401

Novel markers of left ventricular hypertrophy in uremia.

American journal of nephrology 20100401

New therapies: calcimimetics, phosphate binders and vitamin D receptor activators.

Pediatric nephrology (Berlin, Germany) 20100401

[Treatment of secondary hyperparathyroidism resistant to conventional therapy and tertiary hyperparathyroidism with Cinacalcet: an efficiency strategy].

Nephrologie & therapeutique 20100401

Development and utility of a multi-dimensional grid to assess individual mineral metabolism control in hemodialysis patients: A potential aid for therapeutic decision making?

Hemodialysis international. International Symposium on Home Hemodialysis 20100401

Does concomitant administration of sevelamer and calcium carbonate modify the control of phosphatemia?

Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 20100401

Phosphate binders in CKD: chalking out the differences.

Pediatric nephrology (Berlin, Germany) 20100301

Sevelamer carbonate increases serum bicarbonate in pediatric dialysis patients.

Pediatric nephrology (Berlin, Germany) 20100201

Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy?

Clinical journal of the American Society of Nephrology : CJASN 20100201

A randomized, parallel, open-label study to compare once-daily sevelamer carbonate powder dosing with thrice-daily sevelamer hydrochloride tablet dosing in CKD patients on hemodialysis.

American journal of kidney diseases : the official journal of the National Kidney Foundation 20100201

Interventions for bone disease in children with chronic kidney disease.

The Cochrane database of systematic reviews 20100120

Sevelamer carbonate.

The Annals of pharmacotherapy 20100101

Metal ion and vitamin adsorption profiles of phosphate binder ion-exchange resins.

Clinical nephrology 20100101

Ten-year experience with sevelamer and calcium salts as phosphate binders.

Clinical journal of the American Society of Nephrology : CJASN 20100101

The effect of sevelamer hydrochloride and calcium-based phosphate binders on mortality in hemodialysis patients: a need for more research.

The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists 20100101

Impact of calcium, phosphate, PTH abnormalities and management on mortality in hemodialysis: results from the RISCAVID study.

Journal of nephrology 20100101

Phosphate binders, cardiovascular calcifications and mortality: do we need another survival study with sevelamer?

Journal of nephrology 20100101

Sevelamer decreases systemic inflammation in parallel to a reduction in endotoxemia.

Blood purification 20100101

Meta-analysis comparing sevelamer and calcium-based phosphate binders on cardiovascular calcification in hemodialysis patients.

Nephron. Clinical practice 20100101

A comparative study of 2 new phosphate binders (sevelamer and lanthanum carbonate) in routine clinical practice.

Journal of nephrology 20100101

[Phosphorus binders: preferences of patients on haemodialysis and its impact on treatment compliance and phosphorus control].

Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20100101

Sevelamer carbonate reduces inflammation and endotoxemia in an animal model of uremia.

Blood purification 20100101

The control of hyperphosphatemia in renal failure: between vascular calcification and inflammation.

Blood purification 20100101

A randomized, crossover design study of sevelamer carbonate powder and sevelamer hydrochloride tablets in chronic kidney disease patients on haemodialysis.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20091201

Economic evaluation of sevelamer versus calcium-based phosphate binders in hemodialysis patients: a secondary analysis using centers for Medicare & Medicaid services data.

Clinical journal of the American Society of Nephrology : CJASN 20091201

Uremic toxins originating from colonic microbial metabolism.

Kidney international. Supplement 20091201

Endotoxin-binding affinity of sevelamer: a potential novel anti-inflammatory mechanism.

Kidney international. Supplement 20091201

Sevelamer and the bone-vascular axis in chronic kidney disease: bone turnover, inflammation, and calcification regulation.

Kidney international. Supplement 20091201

Lanthanum carbonate: a review of its use in lowering serum phosphate in patients with end-stage renal disease.

Drugs 20091112

The effects of calcium-based versus non-calcium-based phosphate binders on mortality among patients with chronic kidney disease: a meta-analysis.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20091001

Sevelamer versus calcium-based phosphate binders in chronic kidney disease: what should we conclude from the evidence to date?

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20091001

Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.

American journal of kidney diseases : the official journal of the National Kidney Foundation 20091001

Lanthanum carbonate vs. sevelamer hydrochloride for the reduction of serum phosphorus in hemodialysis patients: a crossover study.

Clinical nephrology 20091001

A bitter pill to swallow.

Clinical nephrology 20091001

Sevelamer hydrochloride use and circulating endotoxin in hemodialysis patients: a pilot cross-sectional study.

Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation 20090901

Sevelamer reduces the efficacy of many other drugs.

Prescrire international 20090801

Response of different PTH assays to therapy with sevelamer or CaCO3 and active vitamin D sterols.

Pediatric nephrology (Berlin, Germany) 20090701

Effect of phosphate binders on oxidative stress and inflammation markers in hemodialysis patients.

Hemodialysis international. International Symposium on Home Hemodialysis 20090701

[Clinical aspect of recent progress in phosphate metabolism. Phosphate retension, a powerful risk factor for mortality in chronic kidney disease (CKD)].

Clinical calcium 20090601

[Clinical aspect of recent progress in phosphate metabolism. Management of hyperphosphagtemia].

Clinical calcium 20090601

Oral phosphate binders.

Kidney international 20090501

Comparison of sevelamer hydrochloride and sevelamer carbonate: risk of metabolic acidosis and clinical implications.

Pharmacotherapy 20090501

Vascular calcification and secondary hyperparathyroidism of severe chronic kidney disease and its relation to serum phosphate and calcium levels.

British journal of pharmacology 20090401

[Chronic kidney disease (CKD) and bone. Control of CKD-MBD from the viewpoint of the medical cost].

Clinical calcium 20090401

[Chronic kidney disease (CKD) and bone. Targets of serum calcium, phosphate, and parathyroid hormone levels and their controls in maintenance dialysis patients].

Clinical calcium 20090401

[Chronic kidney disease (CKD) and bone. Vascular calcification in CKD].

Clinical calcium 20090401

[The use of sevelamer in the treatment of resistant hyperphosphataemia in children with chronic renal disease].

Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego 20090401

Peripheral vascular calcification in long-haemodialysis patients: associated factors and survival consequences.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20090301

The use of phosphate binders: data from contributors to the European Practice Database.

Journal of renal care 20090301

Update on the treatment of chronic kidney disease-mineral and bone disorder.

Journal of renal care 20090301

Oral phosphate binders for the management of serum phosphate levels in dialysis patients.

Journal of renal care 20090301

[Management of phosphate in chronic kidney disease--Chemistry and history of phosphate binder].

Clinical calcium 20090201

[Management of hyperphosphatemia ; phosphate-binder].

Clinical calcium 20090201

[Use of phosphate binder in predialysis patients].

Clinical calcium 20090201

[Novel phosphate binders under development].

Clinical calcium 20090201

[To facilitate the compliance of phosphate binder for the control of hyperphosphatemia in chronic kidney disease patients].

Clinical calcium 20090201

The control of hyperphosphatemia in chronic kidney disease: which phosphate binder?

The International journal of artificial organs 20090201

Effect of sevelamer hydrochloride on bone in experimental uremic rats.

Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 20090201

Prevention and management of hyperphosphatemia with sevelamer in Canada: health and economic consequences.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20090101

Diaminobutane (DAB) dendrimers are potent binders of oral phosphate.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20090101

Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20090101

Paricalcitol treatment of secondary hyperparathyroidism in hemodialysis patients on sevelamer hydrochloride: which dialysate calcium concentration to use?

Blood purification 20090101

Blockage of the renin-angiotensin system attenuates mortality but not vascular calcification in uremic rats: sevelamer carbonate prevents vascular calcification.

American journal of nephrology 20090101

Familial tumoral calcinosis caused by a novel FGF23 mutation: response to induction of tubular renal acidosis with acetazolamide and the non-calcium phosphate binder sevelamer.

Hormone research 20090101

[Treating distal calciphylaxis with therapy associated with sevelamer and bisphosphonates].

Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20090101

Sevelamer decreases serum uric acid concentration through adsorption of uric acid in maintenance hemodialysis patients.

Internal medicine (Tokyo, Japan) 20090101

[Multiple peritrochanteric and pubic calcifications in a young woman on hemodialysis with severe renal osteodystrophy successfully treated with sevelamer+cinacalcet+paracalcitol combination therapy].

Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia 20090101

Strategies to manage low-bone turnover.

Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20090101

Vascular calcification and QT interval in incident hemodialysis patients.

Journal of nephrology 20090101

Sevelamer restores bone volume and improves bone microarchitecture and strength in aged ovariectomized rats.

Endocrinology 20081201

The CARE-2 study results: setting the record straight.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20081201

Association of changes in bone remodeling and coronary calcification in hemodialysis patients: a prospective study.

American journal of kidney diseases : the official journal of the National Kidney Foundation 20081201

Treatment of hyperphosphatemia with sevelamer hydrochloride in dialysis patients: effects on vascular calcification, bone and a close look into the survival data.

Kidney international. Supplement 20081201

A review article: sevelamer hydrochloride and metabolic acidosis in dialysis patients.

Cardiovascular & hematological disorders drug targets 20081201

Progression of calcification in the Calcium Acetate Renagel Evaluation-2 (CARE-2) Study.

American journal of kidney diseases : the official journal of the National Kidney Foundation 20081101

Hyperphosphatemia in the Calcium Acetate Renagel Evaluation-2 (CARE-2) Study.

American journal of kidney diseases : the official journal of the National Kidney Foundation 20081101

Binder wars.

American journal of kidney diseases : the official journal of the National Kidney Foundation 20081101

Effects of treatment of renal osteodystrophy on bone histology.

Clinical journal of the American Society of Nephrology : CJASN 20081101

New strategies in treatment of mineral and bone disorders and associated cardiovascular disease in patients with chronic kidney disease.

Recent patents on cardiovascular drug discovery 20081101

Overcoming obstacles for adherence to phosphate binding medication in dialysis patients: a qualitative study.

Pharmacy world & science : PWS 20081001

Calcium-containing phosphate binders in dialysis patients with cardiovascular calcifications: should we CARE-2 avoid them?

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20081001

Linking Centers for Medicare & Medicaid Services data with prospective DCOR trial data: methods and data comparison results.

Hemodialysis international. International Symposium on Home Hemodialysis 20081001

Calcium load during administration of calcium carbonate or sevelamer in individuals with normal renal function.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20080901

Sevelamer hydrochloride: a novel treatment of hyperphosphatemia associated with tumor lysis syndrome in children.

Pediatric blood & cancer 20080701

Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis.

Clinical journal of the American Society of Nephrology : CJASN 20080701

Time-dependent effect of sevelamerHCl on the cardiovascular system.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20080601

Sevelamer.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20080601

A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study.

American journal of kidney diseases : the official journal of the National Kidney Foundation 20080601

Buffering effects of calcium carbonate as clarified by sevelamer hydrochloride monotherapy.

Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 20080601

Lack of mortality benefit with sevelamer.

Kidney international 20080501

Lower gastrointestinal bleeding: association with Sevelamer use.

World journal of gastroenterology 20080428

Comparison of chronic renal failure rats and modification of the preparation protocol as a hyperphosphataemia model.

Nephrology (Carlton, Vic.) 20080401

Use of sevelamer hydrochloride as an oxalate binder.

The Journal of urology 20080401

Comparison of sevelamer hydrochloride with colestimide, administered alone or in combination with calcium carbonate, in patients on hemodialysis.

Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 20080401

[Treatment of secondary hyperparathyroidism in renal insufficiency: role of calcitriol, sevelamer and cinacalcet].

Revue medicale suisse 20080305

Ectopic mineralization of connective tissue in Abcc6-/- mice: effects of dietary modifications and a phosphate binder--a preliminary study.

Experimental dermatology 20080301

K/DOQI-recommended intact PTH levels do not prevent low-turnover bone disease in hemodialysis patients.

Kidney international 20080301

Phosphate binder choice in dialysis patients: a call for evidence-based rather than marketing-based clinical practice.

American journal of kidney diseases : the official journal of the National Kidney Foundation 20080301

A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data.

American journal of kidney diseases : the official journal of the National Kidney Foundation 20080301

Effect of sevelamer on mineral and lipid abnormalities in hemodialysis patients.

Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia 20080301

Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients.

Journal of the American Society of Nephrology : JASN 20080201

An economic evaluation of sevelamer in patients new to dialysis.

Current medical research and opinion 20080201

Block randomized trial evidencing lower mortality with sevelamer compared with calcium phosphate binder in incident dialysis patients.

Kidney international 20080201

Phosphate binders and timing of levothyroxine administration.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20080101

Effects of sevelamer and calcium-based phosphate binders on lipid and inflammatory markers in hemodialysis patients.

American journal of nephrology 20080101

After several years of witchhunting, can calcium-based phosphate binding be released on probation?

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20080101

Short-term treatment with sevelamer increases serum fetuin-a concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patients.

Clinical journal of the American Society of Nephrology : CJASN 20080101

The interscan variation of CT coronary artery calcification score: analysis of the Calcium Acetate Renagel Comparison (CARE)-2 study.

Academic radiology 20080101

Sevelamer hydrochloride: a review of its use for hyperphosphataemia in patients with end-stage renal disease on haemodialysis.

Drugs 20080101

Calciphylaxis of both proximal and distal distribution.

Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia 20080101

Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients: results of a randomized clinical trial.

Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation 20080101

Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. No good evidence to promote a general use of sevelamer.

Kidney international 20080101

Efficacy and side effects of sevelamer hydrochloride as sole phosphate binder in peritoneal dialysis patients with severe hyperphosphatemia.

Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis 20080101

Effects of sevelamer on the progression of vascular calcification in patients on chronic haemodialysis.

Nephron. Clinical practice 20080101

Preventive measures and new pharmacological approaches of calcium and phosphate disorders.

Contributions to nephrology 20080101

Endotoxin-binding affinity of sevelamer hydrochloride.

American journal of nephrology 20080101

Nonphosphate-binding effects of sevelamer--are they of clinical relevance?

Seminars in dialysis 20080101

Calcium and the saga of the binders: accumulating controversy, or building consensus?

International urology and nephrology 20080101

[Clinical advances in vascular calcification].

Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20080101

[Control of phosphorus and treatment with vitamin D in chronic kidney disease prior to the start of dialysis].

Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20080101

[Phosphorus (P) chelant in dialysis: efficacy and cost. Peritoneal dialysis solutions].

Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20080101

Phosphate binder impact on bone remodeling and coronary calcification--results from the BRiC study.

Nephron. Clinical practice 20080101

Switching from calcium carbonate to sevelamer hydrochloride has suppressive effects on the progression of aortic calcification in hemodialysis patients: assessment using plain chest X-ray films.

Renal failure 20080101

Chronic acid-base perturbations in hemodialysis patients treated with sevelamer hydrochloride: a two-year follow-up study.

Artificial organs 20071201

A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate.

Current medical research and opinion 20071201

Survival in end stage renal disease: calcium carbonate vs. sevelamer.

Journal of clinical pharmacy and therapeutics 20071201

Sevelamer hydrochloride improves hyperphosphatemia in hemodialysis patients with low bone turnover rate and low intact parathyroid hormone levels.

Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 20071201

[In-vitro study of the drug interactions between Miglitol, an alpha-glucosidase inhibitor, and adsorbents].

Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 20071201

CKD-MBD: impact on management of kidney disease.

Clinical and experimental nephrology 20071201

A randomized, double-blind, crossover design study of sevelamer hydrochloride and sevelamer carbonate in patients on hemodialysis.

Clinical nephrology 20071201

Study probes best choice of drug to reduce phosphate in patients on dialysis.

JAMA 20071107

Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients.

Kidney international 20071101

The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer.

Kidney international 20071101

The details bedevil DCOR.

Kidney international 20071101

Relative in vitro efficacy of the phosphate binders lanthanum carbonate and sevelamer hydrochloride.

Journal of pharmaceutical sciences 20071001

Economic evaluation of sevelamer in patients with end-stage renal disease.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20071001

Effect of sevelamer on aortic pulse wave velocity in patients on hemodialysis: a prospective observational study.

Hemodialysis international. International Symposium on Home Hemodialysis 20071001

Sevelamer: a promising but unproven drug.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20071001

Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20071001

Calcium and phosphorus control in patients undergoing hemodialysis: from the view-points of activities of daily living.

Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 20071001

Optimising the treatment of hyperphosphatemia and vascular calcification in chronic kidney disease.

Expert opinion on emerging drugs 20070901

Emerging drugs for hyperphosphatemia.

Expert opinion on emerging drugs 20070901

Hyperostosis with hyperphosphatemia and tumoral calcinosis: a case report.

Pediatric nephrology (Berlin, Germany) 20070801

Transient acid exposure increases sevelamer HCl phosphate binding.

Journal of pharmaceutical sciences 20070801

New medications which decrease levothyroxine absorption.

Thyroid : official journal of the American Thyroid Association 20070801

Sevelamer and extension studies.

Kidney international 20070701

Influence of sevelamer on mineral metabolism and hyperparathyroidism in Japanese hemodialysis patients.

Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 20070601

Does Sevelamer reduce mortality by slowing of progression of coronary calcification?

Kidney international 20070601

[Phosphate binder up to date].

Clinical calcium 20070501

Sevelamer hydrochloride exacerbates metabolic acidosis in hemodialysis patients, depending on the dosage.

Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 20070401

Hyperphosphatemia in dialysis patients: the therapeutic role of lanthanum carbonate.

The International journal of artificial organs 20070401

Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients.

Kidney international 20070301

Control of hyperphosphatemia beyond phosphate.

Kidney international 20070301

[Arteriosclerosis and vascular calcification in chronic kidney disease (CKD) patients].

Clinical calcium 20070301

[Relationship between sevelamer HCl and vascular calcification].

Clinical calcium 20070301

[How to reach and maintain the K/DOQI recommendations for bone and mineral metabolism in patients undergoing haemodialysis: an efficient strategy].

Nephrologie & therapeutique 20070301

Cost of applying the K/DOQI guidelines for bone metabolism and disease to a cohort of chronic hemodialysis patients.

Kidney international 20070201

Potential usefulness of sevelamer hydrochloride to improve cardiac outcome in patients with coronary disease and normal renal function.

Medical hypotheses 20070101

Reversal of the adynamic bone disorder and decreased vascular calcification in chronic kidney disease by sevelamer carbonate therapy.

Journal of the American Society of Nephrology : JASN 20070101

Animal models--what they can tell us about vascular calcification in CKD.

Seminars in dialysis 20070101

Vascular calcification and disordered mineral metabolism in dialysis patients.

Seminars in dialysis 20070101

Vascular calcification--a new window on the cardiovascular system: role of agents used to manipulate skeletal integrity.

Seminars in dialysis 20070101

Final Word: The binders wars 2007-2017: 'The truth is out there somewhere...'.

Seminars in dialysis 20070101

Causes and consequences of increased arterial stiffness in chronic kidney disease patients.

Kidney & blood pressure research 20070101

Effect of sevelamer hydrochloride on markers of bone turnover in Japanese dialysis patients with low biointact PTH levels.

Internal medicine (Tokyo, Japan) 20070101

Sevelamer and other anion-exchange resins in the prevention and treatment of hyperphosphataemia in chronic renal failure.

Nephron. Physiology 20070101

Consequences of the implementation of K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease in a population of patients on chronic hemodialysis.

Journal of nephrology 20070101

[Either calcium carbonate or sevelamer decreases urinary oxalate excretion in chronic renal failure patients].

Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20070101

Sevelamer hydrochloride in peritoneal dialysis patients: results of a multicenter cross-sectional study.

Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis 20070101

Sevelamer treatment strategy in peritoneal dialysis patients: conventional dose does not make best use of resources.

Journal of nephrology 20070101

Clinical consequences and novel therapy of hyperphosphatemia: Lanthanum carbonate for dialysis patients.

Recent patents on cardiovascular drug discovery 20070101

[K-DOQI guidelines for calcium and phosphorus metabolism in chronic kidney disease: outcomes, compliance and new drugs for treatment].

Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20070101

Pleiotropic effects of the non-calcium phosphate binder sevelamer.

Kidney international. Supplement 20061201

Accelerated vascular calcification and relative hypoparathyroidism in incident haemodialysis diabetic patients receiving calcium binders.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20061101

Review of dialysate calcium concentration in hemodialysis.

Hemodialysis international. International Symposium on Home Hemodialysis 20061001

Emerging strategies for lowering serum phosphorous in patients with end-stage renal disease.

Expert opinion on pharmacotherapy 20061001

The safety of phosphate binders.

Expert opinion on drug safety 20060901

Results of a randomized crossover study comparing once-daily and thrice-daily sevelamer dosing.

American journal of kidney diseases : the official journal of the National Kidney Foundation 20060901

Phosphate binders and management of hyperphosphataemia in end-stage renal disease.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20060801

Novel dosage forms and regimens for sevelamer-based phosphate binders.

Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation 20060701

Molecular modeling studies of the binding characteristics of phosphates to sevelamer hydrochloride--assessing a novel technique to reduce phosphates contamination.

International journal of environmental research and public health 20060601

Diarrhea induced by high doses of nicotinamide in dialysis patients.

Kidney international 20060501

Phosphate binders.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20060415

A randomized crossover trial comparing sevelamer with calcium acetate in children with CKD.

American journal of kidney diseases : the official journal of the National Kidney Foundation 20060401

Long-term comparison of sevelamer hydrochloride to calcium-containing phosphate binders.

Nephrology (Carlton, Vic.) 20060401

Sevelamer hydrochloride reverses parathyroid gland enlargement via regression of cell hypertrophy but not apoptosis in rats with chronic renal insufficiency.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20060301

Sevelamer therapy for pediatric end-stage renal disease.

Pharmacotherapy 20060301

Effects of sevelamer and calcium on coronary artery calcification in patients new to dialysis: time for better controlled clinical trials.

Kidney international 20060301

Phosphate binders.

The Medical letter on drugs and therapeutics 20060213

Effect of manipulating serum phosphorus with phosphate binder on circulating PTH and FGF23 in renal failure rats.

Kidney international 20060201

Sevelamer hydrochloride in peritoneal dialysis patients: ca' canny but ca' awa'.

Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis 20060101

Sevelamer hydrochloride versus aluminum hydroxide: effect on serum phosphorus and lipids in CAPD patients.

Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis 20060101

Sevelamer worsens metabolic acidosis in hemodialysis patients.

Journal of nephrology 20060101

Long-term management of sevelamer hydrochloride-induced metabolic acidosis aggravation and hyperkalemia in hemodialysis patients.

Renal failure 20060101

A comparison of sevelamer hydrochloride with calcium acetate on biomarkers of bone turnover in hemodialysis patients.

Renal failure 20060101

Hyperphosphatemia and phosphate binders.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20051115

Sevelamer prevents uremia-enhanced atherosclerosis progression in apolipoprotein E-deficient mice.

Circulation 20051101

Drug interaction between sevelamer and furosemide.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20051001

Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis.

Kidney international 20051001

Gastric pH, sevelamer hydrochloride and omeprazole.

Clinical nephrology 20051001

The effect of sevelamer on tacrolimus target levels.

Transplantation 20050915

[Treatment of adynamic bone disease with the complete replacement from calcium carbonate to sevelamer hydrochloride].

Clinical calcium 20050901

[Treatment with phosphate binder (sevelamer hydrochloride, calcium carbonate) based on PTH].

Clinical calcium 20050901

[Defining the role of sevelamer chloride as a therapeutic agent for management of phosphate in patient with hemodialysis].

Clinical calcium 20050901

[Effects of intermittent treatment with sevelamer hydrochloride on parathyroid hyperplasia and vascular calcification in rats with chronic kidney disease].

Clinical calcium 20050901

[Clinical analysis of time-course changes in minerals and parathyroid hormone levels during treatment with phosphate binders in hemodialysis patients with secondary hyperparathyroidism].

Clinical calcium 20050901

[Control of calcium and phosphate in hemodialysis patients].

Clinical calcium 20050901

[Relationship between serum calcium level and PTH concentration proved with sevelamer hydrochloride].

Clinical calcium 20050901

[Clinical effect of introduction of sevelamer hydrochloride in patients with hyperphosphatemia undergoing maintenance dialysis].

Clinical calcium 20050901

[Sevelamer hydrochloride and K/DOQI guidelines].

Clinical calcium 20050901

[Sevelamer hydrochloride and vitamin D for controlling serum calcium, phosphorus and bone metabolism in patients undergoing hemodialysis].

Clinical calcium 20050901

[Role of sevelamer hydrochloride in the Coronary Artery Calcification Index].

Clinical calcium 20050901

[Management of secondary hyperparathyroidism].

Clinical calcium 20050901

[Present status and problems in vitamin D and sevelamer therapy (discussion)].

Clinical calcium 20050901

Length of interdialytic interval influences serum calcium and phosphorus concentrations.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20050801

Two year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20050801

Sevelamer controls parathyroid hormone-induced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vitamin D sterols.

Journal of the American Society of Nephrology : JASN 20050801

Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients.